1 week Ago By ABMN Staff
D. Boral Capital restated their buy rating on shares of Immunic ( NASDAQ:IMUX – Free Report ) in a research report sent to investors on Thursday morning, Benzinga reports. The firm currently has a $17.
00 target price on the stock. A number of other equities analysts also recently weighed in on the company. William Blair began coverage on Immunic in a research report on Tuesday, March 25th.
They set an “outperform” rating for the company. StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research report on Thursday, March 20th.
Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Immunic in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the stock.
According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $13.20. Check Out Our Latest Stock Report on Immunic Immunic Price Performance Institutional Trading of Immunic Several institutional investors and hedge funds have recently added to or reduced their stakes in the company.
Invesco Ltd. acquired a new position in shares of Immunic during the 4th quarter worth about $37,000. Virtu Financial LLC acquired a new position in Immunic during the third quarter worth approximately $50,000.
HB Wealth Management LLC bought a new stake in Immunic in the fourth quarter valued at approximately $81,000. Barclays PLC bought a new stake in Immunic in the fourth quarter valued at approximately $84,000. Finally, Jane Street Group LLC lifted its position in shares of Immunic by 121.
4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after buying an additional 38,553 shares during the last quarter. 51.
82% of the stock is owned by institutional investors. Immunic Company Profile ( Get Free Report ) Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Featured Articles Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter ..
